Rapport Therapeutics, Inc./$RAPP
Rapport Therapeutics shares are trading higher after the company provided corporate updates and announced full enrollment of their Phase 2a trial for RAP-219 in refractory focal epilepsy.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Ticker
$RAPP
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
69
ISIN
US75383L1026
Website
RAPP Metrics
BasicAdvanced
$302M
-
-$2.74
-
-
Price and volume
Market cap
$302M
52-week high
$12.85
52-week low
$6.43
Average daily volume
150K
Financial strength
Current ratio
31.01
Quick ratio
30.415
Long term debt to equity
2.391
Total debt to equity
2.744
Management effectiveness
Return on assets (TTM)
-22.89%
Return on equity (TTM)
-33.14%
Valuation
Price to book
1.06
Price to tangible book (TTM)
1.06
Price to free cash flow (TTM)
-3.477
Growth
Earnings per share change (TTM)
-91.03%
RAPP News
AllArticlesVideos
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
GlobeNewsWire·5 hours ago
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·7 days ago
Rapport Therapeutics to Host 2025 Investor and Analyst Day
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rapport Therapeutics, Inc. stock?
Rapport Therapeutics, Inc. (RAPP) has a market cap of $302M as of June 03, 2025.
What is the P/E ratio for Rapport Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Rapport Therapeutics, Inc. (RAPP) stock is 0 as of June 03, 2025.
Does Rapport Therapeutics, Inc. stock pay dividends?
No, Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders as of June 03, 2025.
When is the next Rapport Therapeutics, Inc. dividend payment date?
Rapport Therapeutics, Inc. (RAPP) stock does not pay dividends to its shareholders.
What is the beta indicator for Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc. (RAPP) does not currently have a Beta indicator.